AR123793A1 - Compuestos de triazolopiridinilo como inhibidores de quinasas - Google Patents
Compuestos de triazolopiridinilo como inhibidores de quinasasInfo
- Publication number
- AR123793A1 AR123793A1 ARP210102843A ARP210102843A AR123793A1 AR 123793 A1 AR123793 A1 AR 123793A1 AR P210102843 A ARP210102843 A AR P210102843A AR P210102843 A ARP210102843 A AR P210102843A AR 123793 A1 AR123793 A1 AR 123793A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- haloalkyl
- deuteroc1
- deuteroalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que tienen la fórmula (1) y enantiómeros y diastereómeros, estereoisómeros, sales farmacéuticamente aceptables de los mismos, son útiles como moduladores de quinasas, incluida la modulación RIPK1. Todas las variables son como se definen en el presente documento. Reivindicación 1: Un compuesto que tiene la fórmula (1), o una sal del mismo, en donde R¹ es H, alquilo C₁₋₃, alcoxilo C₁₋₃, haloalquilo C₁₋₃, haloalcoxilo C₁₋₃, deuteroalquilo C₁₋₃, deuteroalcoxilo C₁₋₃, halógeno, o ciclopropilo; R² es H, o halo; R³ es H, halo, o alquilo C₁₋₃ o deuteroalquilo C₁₋₃; R⁴ es H o F; R⁵ᵃ y R⁵ᵇ son cada uno independientemente H, deuterio, alquilo C₁₋₃ o haloalquilo C₁₋₃; alternativamente, R⁵ᵃ y R⁵ᵇ se unen para formar ciclopropilo; R⁶ᵃ y R⁶ᵇ son cada uno independientemente H, deuterio, OH, F, alquilo C₁₋₃, o C(O)-4-fluorofenilo; alternativamente, R⁶ᵃ y R⁶ᵇ son =O, o se unen para formar ciclopropilo o oxetanilo; R⁷ᵃ y R⁷ᵇ son cada uno independientemente H, deuterio, OH, OP(O)(OR)₂, OC(O)NH₂, NH₂, F, alquilo C₁₋₃, alcoxi C₁₋₃, OCD₃, o haloalquilo C₁₋₃; alternativamente, R⁷ᵃ y R⁷ᵇ son =O, o se unen para formar ciclopropilo o oxetanilo; R es H o alquilo C₁₋₃; R⁸ es H, F, Cl, alquilo C₁₋₃, alcoxi C₁₋₃, deuteroalquilo C₁₋₃, o deuteroalcoxi C₁₋₃; R⁹ es H o CH₃; el anillo Z es fenilo, un anillo heteroarilo de 6 miembros que tiene 1 - 2 átomos de nitrógeno, ciclohexilo, ciclopentilo, o ciclobutilo; Y es F, Cl, alquilo C₁₋₃, alcoxi C₁₋₃, CN, haloalquilo C₁₋₃, haloalcoxi C₁₋₃, deuteroalquilo C₁₋₃, deuteroalcoxi C₁₋₃, C(O)OCH₃, o C&
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093463P | 2020-10-19 | 2020-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123793A1 true AR123793A1 (es) | 2023-01-11 |
Family
ID=78536657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102843A AR123793A1 (es) | 2020-10-19 | 2021-10-14 | Compuestos de triazolopiridinilo como inhibidores de quinasas |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11767322B2 (es) |
| EP (2) | EP4364737A3 (es) |
| JP (1) | JP7730897B2 (es) |
| KR (1) | KR20230092960A (es) |
| CN (1) | CN116802181A (es) |
| AR (1) | AR123793A1 (es) |
| AU (1) | AU2021364302A1 (es) |
| CA (1) | CA3196059A1 (es) |
| CL (1) | CL2023001123A1 (es) |
| CO (1) | CO2023004926A2 (es) |
| DK (1) | DK4229056T3 (es) |
| ES (1) | ES2987662T3 (es) |
| FI (1) | FI4229056T3 (es) |
| HR (1) | HRP20240739T1 (es) |
| HU (1) | HUE067776T2 (es) |
| IL (1) | IL302113A (es) |
| LT (1) | LT4229056T (es) |
| MX (1) | MX2023004492A (es) |
| PE (1) | PE20240219A1 (es) |
| PL (1) | PL4229056T3 (es) |
| PT (1) | PT4229056T (es) |
| RS (1) | RS65620B1 (es) |
| SI (1) | SI4229056T1 (es) |
| SM (1) | SMT202400242T1 (es) |
| TW (1) | TW202233614A (es) |
| WO (1) | WO2022086828A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018148626A1 (en) * | 2017-02-13 | 2018-08-16 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| KR20220079593A (ko) | 2019-10-03 | 2022-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 인다졸 카르복스아미드 |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| AR133938A1 (es) | 2023-09-27 | 2025-11-19 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo unidos a éter como inhibidores de cinasa |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077948A1 (ja) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | 抗真菌作用複素環化合物 |
| WO2006004702A1 (en) | 2004-06-25 | 2006-01-12 | Amgen Inc. | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| JPWO2009128520A1 (ja) | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する複素環化合物 |
| WO2010007099A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| JP5589003B2 (ja) | 2009-02-04 | 2014-09-10 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | 脂質障害のような代謝疾患の処置のために有用な［１，３］オキサジン−２−オンの誘導体 |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| CA2914668A1 (en) | 2013-06-10 | 2014-12-18 | Volker Schulze | Novel compounds for the treatment of cancer |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| US10023576B2 (en) | 2014-10-22 | 2018-07-17 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors |
| US10214537B2 (en) | 2014-10-22 | 2019-02-26 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds |
| EP3372604B1 (en) | 2015-11-05 | 2021-12-01 | Sumitomo Chemical Company, Limited | Condensed heterocyclic compound |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| JP7190906B2 (ja) | 2017-01-24 | 2022-12-16 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| WO2018148626A1 (en) | 2017-02-13 | 2018-08-16 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| WO2018237370A1 (en) | 2017-06-23 | 2018-12-27 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same |
| LT3704118T (lt) | 2017-10-30 | 2022-02-25 | Bristol-Myers Squibb Company | Aminoimidazopiridazinai, kaip kinazės inhibitoriai |
| EA202091777A1 (ru) | 2018-01-26 | 2020-10-14 | Бристол-Маерс Сквибб Компани | Аминопирролотриазины в качестве ингибиторов киназы |
| AU2019339355A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| JP7599411B2 (ja) | 2018-09-13 | 2024-12-13 | ブリストル－マイヤーズ スクイブ カンパニー | 受容体相互作用タンパク質キナーゼ１阻害剤（ｒｉｐｋ１）としての１ｈ－インダゾールカルボキサミド |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| CN113508109B (zh) | 2019-03-22 | 2023-02-10 | 劲方医药科技(上海)有限公司 | 取代的杂环酰胺类化合物，其制法与医药上的用途 |
| KR20220079593A (ko) | 2019-10-03 | 2022-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 인다졸 카르복스아미드 |
| CN114230565B (zh) | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2021
- 2021-10-14 AR ARP210102843A patent/AR123793A1/es not_active Application Discontinuation
- 2021-10-18 US US17/503,516 patent/US11767322B2/en active Active
- 2021-10-18 EP EP24159615.4A patent/EP4364737A3/en active Pending
- 2021-10-18 KR KR1020237016535A patent/KR20230092960A/ko active Pending
- 2021-10-18 EP EP21805787.5A patent/EP4229056B1/en active Active
- 2021-10-18 AU AU2021364302A patent/AU2021364302A1/en not_active Abandoned
- 2021-10-18 CA CA3196059A patent/CA3196059A1/en active Pending
- 2021-10-18 IL IL302113A patent/IL302113A/en unknown
- 2021-10-18 SI SI202130138T patent/SI4229056T1/sl unknown
- 2021-10-18 PL PL21805787.5T patent/PL4229056T3/pl unknown
- 2021-10-18 TW TW110138596A patent/TW202233614A/zh unknown
- 2021-10-18 SM SM20240242T patent/SMT202400242T1/it unknown
- 2021-10-18 HU HUE21805787A patent/HUE067776T2/hu unknown
- 2021-10-18 WO PCT/US2021/055340 patent/WO2022086828A1/en not_active Ceased
- 2021-10-18 PE PE2023001446A patent/PE20240219A1/es unknown
- 2021-10-18 MX MX2023004492A patent/MX2023004492A/es unknown
- 2021-10-18 HR HRP20240739TT patent/HRP20240739T1/hr unknown
- 2021-10-18 DK DK21805787.5T patent/DK4229056T3/da active
- 2021-10-18 FI FIEP21805787.5T patent/FI4229056T3/fi active
- 2021-10-18 LT LTEPPCT/US2021/055340T patent/LT4229056T/lt unknown
- 2021-10-18 ES ES21805787T patent/ES2987662T3/es active Active
- 2021-10-18 PT PT218057875T patent/PT4229056T/pt unknown
- 2021-10-18 RS RS20240656A patent/RS65620B1/sr unknown
- 2021-10-18 CN CN202180070933.6A patent/CN116802181A/zh active Pending
- 2021-10-18 JP JP2023523570A patent/JP7730897B2/ja active Active
-
2023
- 2023-04-18 CL CL2023001123A patent/CL2023001123A1/es unknown
- 2023-04-19 CO CONC2023/0004926A patent/CO2023004926A2/es unknown
- 2023-07-06 US US18/347,703 patent/US12110290B2/en active Active
-
2024
- 2024-08-28 US US18/817,352 patent/US20240425505A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123793A1 (es) | Compuestos de triazolopiridinilo como inhibidores de quinasas | |
| AR119821A1 (es) | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR114236A1 (es) | Inhibidores de la gcn2 y usos de los mismos | |
| PE20201202A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| MX2019009555A (es) | Aminotriazolopiridinas como inhibidores de cinasa. | |
| AR091022A1 (es) | Inhibidores del nampt | |
| ES2589558T3 (es) | Derivados de pirimidin pirazolilo | |
| AR130165A1 (es) | Compuestos heterocíclicos, composiciones de los mismos y métodos de tratamiento con ellos | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| PE20212070A1 (es) | Moduladores de trex1 | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR095530A1 (es) | Moduladores de p2x7 | |
| AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| AR096613A1 (es) | Moduladores de la acetil-coa carboxilasa | |
| AR074493A1 (es) | Derivados de quinazolinamida | |
| AR072192A1 (es) | Derivados de tiazolil-piperidina | |
| AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| AR090103A1 (es) | Derivados ciclicos de diaminopirimidina | |
| AR101964A1 (es) | Compuestos de imidazopiridazina como moduladores de pi3k | |
| AR059886A1 (es) | Derivados de amidas como inhibidores de renina | |
| EA201692189A1 (ru) | Соединения фосфина золота (i) в качестве антибактериальных агентов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |